Free Trial
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel
OTCMKTS:BAYRY

Bayer Aktiengesellschaft Q1 2026 Earnings Results & Report

Bayer Aktiengesellschaft logo
$12.24 +0.17 (+1.41%)
As of 10/9/2026 03:59 PM Eastern

Bayer Aktiengesellschaft beat analyst earnings expectations but missed on revenue in its Q1 2026 results, released May 12, 2026. The company reported EPS of $0.79 versus the $0.64 consensus estimate, while revenue of $15.73 billion fell short of the $15.77 billion estimate by $40.51 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens

Bayer Aktiengesellschaft EPS Results

Actual EPS
$0.79
Consensus EPS
$0.64
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Bayer Aktiengesellschaft Revenue Results

Actual Revenue
$15.73 billion
Expected Revenue
$15.77 billion
Beat/Miss
Missed by -$40.51 million
YoY Revenue Growth
N/A

Upcoming Earnings

Bayer Aktiengesellschaft's next earnings date is estimated for Tuesday, November 3, 2026, based on past reporting schedules.

Conference Call Resources

Bayer Aktiengesellschaft Q1 2026 Earnings FAQ

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) reported earnings of $0.79 per share for Q1 2026, beating the consensus estimate of $0.64. The report was announced on Tuesday, May 12, 2026.

Bayer Aktiengesellschaft reported revenue of $15.73 billion for Q1 2026, against a consensus estimate of $15.77 billion.

Bayer Aktiengesellschaft's next earnings date is estimated for Tuesday, November 3, 2026. MarketBeat tracks confirmed and estimated earnings dates for Bayer Aktiengesellschaft on the company's earnings history page.

Bayer Aktiengesellschaft Earnings Headlines

Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting
October 8 at 4:00 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20261007322202/en/Bayer-to-Present-New-Cardiac-Amyloidosis-and-Heart-Failure-Data-at-the-Heart-Failure-Society-of-America-HFSA-Annual-Scientific-Meeting/
U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes
October 8 at 2:30 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20261007583229/en/u.s.-fda-accepts-bayer%e2%80%99s-supplemental-new-drug-application-for-kerendia%c2%ae-finerenone-to-treat-adults-with-chronic-kidney-disease-ckd-without-diabetes/
THE NEXT GREAT FINANCIAL CRISIS (it’s already here)
Weiss Ratings was the only independent firm to warn before the 2008 Financial Crisis. Now it is sounding the alarm again. A new high-risk subprime sector has attracted 3 trillion dollars in investor funds and is already showing signs of collapse, according to the firm. Weiss Ratings outlines five specific steps investors can take to prepare for what could become a severe financial shock.tc pixel
October 10 at 1:00 AM  |  Weiss Ratings (Ad)
Bayer’s Real‑World Prostate Cancer Study Signals Key Trends for Treatment Adoption in Canada
October 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/bayers-realworld-prostate-cancer-study-signals-key-trends-for-treatment-adoption-in-canada?utm_source=marketbeat.com&utm_medium=referral
Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
October 2, 2026  |  wsj.comhttps://www.wsj.com/health/pharma/bayer-to-invest-2-2-billion-in-u-s-pharma-manufacturing-expansion-ec038b86
Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States
October 2, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261002202241/en/bayer-to-invest-2.2-billion-u.s.-dollars-in-a-new-manufacturing-site-in-the-united-states/
See More Bayer Aktiengesellschaft Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bayer Aktiengesellschaft? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bayer Aktiengesellschaft and other key companies, straight to your email.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) is a Germany-based life science company focused on health care and agriculture. Through its Pharmaceuticals, Consumer Health and Crop Science businesses, the company develops and markets products intended to improve human health, everyday self-care and agricultural productivity.

Bayer’s Pharmaceuticals business provides prescription medicines in areas such as cardiovascular disease, women’s health, oncology and specialty medicine. Its Consumer Health division offers nonprescription products in categories including pain relief, nutritional supplements, dermatology and allergy care, with brands such as Aspirin and Claritin. The Crop Science business supplies seeds, crop protection products and digital agricultural solutions for farmers and other agricultural customers.

Founded in 1863, Bayer is headquartered in Leverkusen, Germany, and serves customers in markets around the world. The company expanded its agricultural operations through the acquisition of Monsanto in 2018, adding seed and crop protection businesses to its portfolio. Bayer is led by Chief Executive Officer Bill Anderson, who assumed the role in June 2023.

View Bayer Aktiengesellschaft Profile
Earnings Tools